Researchers who conducted a recent prospective, registry-based cohort study found that the use of once-weekly semaglutide, a glucagon-like peptide-1 receptor agonist, significantly increases the risk of nonarteritic anterior ischemic optic neuropathy (NAION) in patients with type 2 diabetes. The study included over 400,000 patients with type 2 diabetes in Denmark. Findings revealed a doubling of NAION risk in patients using semaglutide compared to nonusers. Further studies are needed to identify high-risk subgroups and explore whether the risk of NAION is specific to semaglutide or extends to the entire GLP-1 RA drug class.

Source: International Journal of Retina and Vitreous